ES3021195T3 - Prodrugs of 2-pmpa for healthy tissue protection during psma-targeted cancer imaging or radiotherapy - Google Patents

Prodrugs of 2-pmpa for healthy tissue protection during psma-targeted cancer imaging or radiotherapy Download PDF

Info

Publication number
ES3021195T3
ES3021195T3 ES18783981T ES18783981T ES3021195T3 ES 3021195 T3 ES3021195 T3 ES 3021195T3 ES 18783981 T ES18783981 T ES 18783981T ES 18783981 T ES18783981 T ES 18783981T ES 3021195 T3 ES3021195 T3 ES 3021195T3
Authority
ES
Spain
Prior art keywords
psma
pmpa
group
alkyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18783981T
Other languages
English (en)
Spanish (es)
Inventor
Barbara Slusher
Michael Nedelcovych
Rana Rais
Clemens Kratochwil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adarga LLC
Johns Hopkins University
Original Assignee
Adarga LLC
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adarga LLC, Johns Hopkins University filed Critical Adarga LLC
Application granted granted Critical
Publication of ES3021195T3 publication Critical patent/ES3021195T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES18783981T 2017-04-11 2018-04-11 Prodrugs of 2-pmpa for healthy tissue protection during psma-targeted cancer imaging or radiotherapy Active ES3021195T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762484219P 2017-04-11 2017-04-11
PCT/US2018/027106 WO2018191376A2 (en) 2017-04-11 2018-04-11 Prodrugs of 2-pmpa for healthy tissue protection during psma-targeted cancer imaging or radiotherapy

Publications (1)

Publication Number Publication Date
ES3021195T3 true ES3021195T3 (en) 2025-05-26

Family

ID=63792979

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18783981T Active ES3021195T3 (en) 2017-04-11 2018-04-11 Prodrugs of 2-pmpa for healthy tissue protection during psma-targeted cancer imaging or radiotherapy

Country Status (10)

Country Link
US (1) US12508271B2 (enExample)
EP (1) EP3609544B1 (enExample)
JP (3) JP2020530007A (enExample)
KR (1) KR102686172B1 (enExample)
CN (1) CN111801121B (enExample)
AU (1) AU2018250609B2 (enExample)
ES (1) ES3021195T3 (enExample)
IL (1) IL269969B2 (enExample)
SG (1) SG11201909513QA (enExample)
WO (1) WO2018191376A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
AU2014336638C1 (en) 2013-10-18 2020-09-17 Novartis Ag Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2015073678A1 (en) 2013-11-14 2015-05-21 Endocyte, Inc. Compounds for positron emission tomography
MX2020010813A (es) 2018-04-17 2021-01-08 Endocyte Inc Metodos de tratamiento de cancer.
JP7429688B2 (ja) * 2018-09-21 2024-02-08 エンドサイト・インコーポレイテッド シールド剤およびそれらの使用
EP3972627A4 (en) 2019-05-20 2023-06-21 Endocyte, Inc. Methods for preparing psma conjugates
WO2021202376A1 (en) * 2020-03-30 2021-10-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for blocking uptake of prostate-specific membrane antigen (psma)-targeted radionuclides by exocrine organs
US20230165980A1 (en) * 2020-04-29 2023-06-01 Novartis Ag Methods for radiolabeling psma binding ligands and their kits
IL297323A (en) * 2020-04-29 2022-12-01 Novartis Ag Methods for radiological labeling of psma-binding ligands and their kits
AU2021352915A1 (en) * 2020-10-01 2023-06-08 Cornell University Methods and compositions for increasing uptake, internalization, and/or retention of small molecule ligands
WO2022106629A1 (en) 2020-11-19 2022-05-27 Novartis Ag Synthesis of prostate specific membrane antigen (psma) ligands
CN113354709B (zh) * 2021-06-03 2023-06-09 江苏华益科技有限公司 一种转移性前列腺癌靶向性药物前体的固相合成方法
EP4536278A4 (en) 2022-06-07 2026-08-12 Actinium Pharmaceuticals Inc CHELETARIANS AND BIFUNCTIONAL CONJUGATES
WO2023239903A1 (en) * 2022-06-09 2023-12-14 Case Western Reserve University Compositions and methods for preventing retention of psma-targeted therapy
AU2024317528A1 (en) 2023-07-31 2026-03-05 Curium Us Llc [177 lu] lutetium-psma it composition and dosimetry, kit, method of making, and method of using thereof
WO2025167998A1 (zh) * 2024-02-06 2025-08-14 北京昌平实验室 膦酸酯骨架的psma靶向偶联物
WO2026120497A1 (en) 2024-12-05 2026-06-11 Novartis Ag Stable radionuclide complex solutions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009046294A2 (en) * 2007-10-03 2009-04-09 Cornell University Treatment of proliferative disorders using antibodies to psma
US10172873B2 (en) * 2014-08-06 2019-01-08 The Johns Hopkins University Methods for treating inflammatory bowel disease using prostate specific membrane antigen (PSMA) inhibitors
ES2908411T3 (es) * 2014-08-06 2022-04-29 Univ Johns Hopkins Profármacos del inhibidor del antígeno de membrana específico de la próstata (PSMA)
JP2017530109A (ja) * 2014-09-08 2017-10-12 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 前立腺癌についてのｐｓｍａを標的とした放射性核種治療中の臓器の保護

Also Published As

Publication number Publication date
JP2020530007A (ja) 2020-10-15
JP2025028897A (ja) 2025-03-05
AU2018250609B2 (en) 2024-05-09
EP3609544C0 (en) 2025-04-09
EP3609544A2 (en) 2020-02-19
CA3059741A1 (en) 2018-10-18
JP2023093545A (ja) 2023-07-04
WO2018191376A3 (en) 2018-12-27
KR102686172B1 (ko) 2024-07-17
WO2018191376A2 (en) 2018-10-18
KR20200059187A (ko) 2020-05-28
EP3609544B1 (en) 2025-04-09
CN111801121B (zh) 2023-12-01
IL269969B2 (en) 2023-04-01
US12508271B2 (en) 2025-12-30
AU2018250609A1 (en) 2019-10-31
SG11201909513QA (en) 2019-11-28
IL269969A (en) 2022-12-01
EP3609544A4 (en) 2020-12-23
US20200069706A1 (en) 2020-03-05
CN111801121A (zh) 2020-10-20

Similar Documents

Publication Publication Date Title
EP3609544B1 (en) Prodrugs of 2-pmpa for healthy tissue protection during psma-targeted cancer imaging or radiotherapy
ES2877572T3 (es) Agentes de alta afinidad dirigidos a antígenos de membrana específicos de próstata para la endorradioterapia del cáncer de próstata
US20230147035A1 (en) Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
ES2912947T3 (es) Agentes de imagenología nuclear y radioterapéuticos dirigidos a la anhidrasa carbónica IX y usos de los mismos
CN120172924A (zh) 用于癌症放射治疗的psma靶向的放射性卤化尿素-聚氨基羧酸盐
CA2961575C (en) Methods for treating inflammatory bowel disease using prostate specific membrane antigen (psma) inhibitors
WO2020028324A1 (en) Long-circulating psma-targeted phototheranostic agent
CA3059741C (en) Prodrugs of 2-pmpa for healthy tissue protection during psma-targeted cancer imaging or radiotherapy
HK40037500A (en) Prodrugs of 2-pmpa for healthy tissue protection during psma-targeted cancer imaging or radiotherapy
HK40037500B (en) Prodrugs of 2-pmpa for healthy tissue protection during psma-targeted cancer imaging or radiotherapy
HK1259764B (en) Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer